Paul K. Audhya - Feb 22, 2025 Form 4 Insider Report for KalVista Pharmaceuticals, Inc. (KALV)

Role: CHIEF MEDICAL OFFICER
Signature: /s/ Benjamin L. Palleiko, Attorney-in-Fact
Stock symbol: KALV
Transactions as of: Feb 22, 2025
Transactions value $: -$23,988
Form type: 4
Date filed: 2/25/2025, 08:37 PM
Previous filing: Feb 19, 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KALV	Common Stock	Options Exercise		+5K	+4.98%		105K	Feb 22, 2025	Direct	F1
transaction	KALV	Common Stock	Sale	-$24K	-2.39K	-2.27%	$10.02	103K	Feb 24, 2025	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KALV	Restricted Stock Units	Award	$0	+100K		$0.00	100K	Feb 21, 2025	Common Stock	100K		Direct	F1, F3
transaction	KALV	Restricted Stock Unit	Options Exercise	$0	-5K	-7.14%	$0.00	65K	Feb 22, 2025	Common Stock	5K		Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
F2	The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
F3	1/16th of the total number of shares underlying the RSUs shall vest on each quarterly anniversary of the Vesting Commencement Date thereafter, for so long as grantee's Service (as defined in the Plan) does not terminate.